All In Biotech

Drug Trial Radar · NCT00421733

The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors

VITAL Study - Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With Renin-angiotensin System Inhibitors

Last checked: Nov 19, 2026Latest source record: Jan 20, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 281 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

281

Actual

Start

Dec 2006

Primary completion

Jun 2009

Study completion Jun 2009

Sponsor

Lead sponsor
AbbottIndustry
Sponsor type
Industry
First posted
Jan 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study objective was to evaluate the safety of paricalcitol capsules and the efficacy of paricalcitol capsules for albuminuria reduction in patients with Chronic Kidney Disease (CKD) who have Type 2 diabetic nephropathy and are receiving optimal angiotensin converting enzyme (ACE) inhibitor and/or angiotensin II receptor blocker (ARB) therapy.

Conditions

  • Diabetic Nephropathy
  • Chronic Kidney Disease

Interventions

  • Zemplar (paricalcitol ) capsulesDrug

    Group 2 - paricalcitol 1 mcg capsules once daily (one paricalcitol 1 mcg capsule once daily and one matching placebo capsule once daily)

  • Zemplar (paricalcitol) capsulesDrug

    Group 3 - paricalcitol 2 mcg capsules once daily (two paricalcitol 1 mcg capsules once daily)

  • PlaceboDrug

    Group 1 - Placebo once daily (two placebo capsules once daily)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to the Last On-treatment Measurement in Urine Albumin to Creatinine Ratio (UACR) Levels Determined From the First Morning Void (FMV) Urine Collections Comparing Placebo to the Combined Paricalcitol Treatment Groups (1 Mcg and 2 Mcg).Time frame: Baseline (within 1 week prior to first treatment) through 24 weeks of treatment

Locations

72 sites in 10 countries. Site status is shown where the registry gives one.

  • Site Reference ID/Investigator# 862

    Phoenix, Arizona

  • Site Reference ID/Investigator# 864

    Fountain Valley, California

  • Site Reference ID/Investigator# 7291

    Yuba City, California

  • Site Reference ID/Investigator# 853

    Hudson, Florida

  • Site Reference ID/Investigator# 867

    Lauderdale Lakes, Florida

  • Site Reference ID/Investigator# 857

    Pembroke Pines, Florida

  • Site Reference ID/Investigator# 8901

    West Palm Beach, Florida

  • Site Reference ID/Investigator# 7113

    Roswell, Georgia

  • Site Reference ID/Investigator# 2531

    Chicago, Illinois

  • Site Reference ID/Investigator# 3371

    Evanston, Illinois

  • Site Reference ID/Investigator# 869

    Indianapolis, Indiana

  • Site Reference ID/Investigator# 8054

    Baton Rouge, Louisiana

  • Site Reference ID/Investigator# 854

    Rockville, Maryland

  • Site Reference ID/Investigator# 6281

    Boston, Massachusetts

  • Site Reference ID/Investigator# 859

    Brooklyn Center, Minnesota

  • Site Reference ID/Investigator# 7214

    Omaha, Nebraska

  • Site Reference ID/Investigator# 8046

    Albany, New York

  • Site Reference ID/Investigator# 866

    Charlotte, North Carolina

  • Site Reference ID/Investigator# 8039

    Greenville, North Carolina

  • Site Reference ID/Investigator# 8053

    Morehead City, North Carolina

  • Site Reference ID/Investigator# 6626

    Winston-Salem, North Carolina

  • Site Reference ID/Investigator# 7495

    Carlisle, Pennsylvania

  • Site Reference ID/Investigator# 9061

    Dallas, Texas

  • Site Reference ID/Investigator# 8325

    Dallas, Texas

  • Site Reference ID/Investigator# 856

    Dallas, Texas

  • Site Reference ID/Investigator# 7494

    San Antonio, Texas

  • Site Reference ID/Investigator# 774

    San Antonio, Texas

  • Site Reference ID/Investigator# 6316

    Düsseldorf, Germany

  • Site Reference ID/Investigator# 5167

    Hanover, Germany

  • Site Reference ID/Investigator# 6302

    Ludwigshafen, Germany

  • Site Reference ID/Investigator# 6314

    Athens, Greece

  • Site Reference ID/Investigator# 6306

    Ioannina, Greece

  • Site Reference ID/Investigator# 5631

    Thessaloniki, Greece

  • Site Reference ID/Investigator# 6310

    Thessaloniki, Greece

  • Site Reference ID/Investigator# 6312

    Bergamo, Italy

  • Site Reference ID/Investigator# 6303

    Brescia, Italy

  • Site Reference ID/Investigator# 6309

    Milan, Italy

  • Site Reference ID/Investigator# 6210

    Modena, Italy

  • Site Reference ID/Investigator# 6207

    Groningen, Netherlands

  • Site Reference ID/Investigator# 6304

    Bydgoszcz, Poland

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.